Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (175387)	7/25/2021 6:54:29 PM
From: Julius Wong	Respond to of 219498

Spaniards Put Faith in COVID-19 Vaccines Even as Cases Surge Spain has an important asset as it tries to stamp out a wave of infections that is steadily filling hospitals with younger COVID-19 patients. Hundreds of people queue to be vaccinated against COVID-19 at the Enfermera Isabel Zendal Hospital in Madrid, Spain, Tuesday, July 7, 2021. Spain is trying to stamp out a new wave of COVID-19 among its youth thanks to a robust vaccination program that is widely supported. Spain like the rest of the European Union got off to a slow start to compared to the United States and Britain when the first vaccines were released. (AP Photo/Olmo Calvo) THE ASSOCIATED PRESS By JOSEPH WILSON, Associated Press BARCELONA, Spain (AP) — Like many of Spain’s 20-somethings, Sergio Rosado has seen the new, more contagious coronavirus strain strike those too eager to cut loose when authorities rolled back health restrictions with vaccinations picking up pace. But the 22-year-old student shares the country's widespread public trust in the vaccines, and Rosado plans to get his shots as soon as his turn comes. “I have friends that have caught COVID-19 at big parties. Lots of people I know have caught it,” Rosado said. “I did go out too, but to places without many people and in controlled spaces, and with face masks.” Spain, like its fellow European Union members, got off to a slow start in administering shots compared to Britain and the United States after regulators approved the first vaccines. But once deliveries by drugmakers started flowing to meet demand, the country quickly made up ground. More usnews.com

To: TobagoJack who wrote (175387)	7/25/2021 6:58:03 PM
From: Snowshoe	Read Replies (3) \| Respond to of 219498

re "Of the approximately 15,000 who had received one shot and got infected, about 50 died. Among almost 2,000 fully vaccinated people, only four died from the disease, showing a case fatality rate of 0.21%." Note: I got the Pfizer two-shot sequence earlier this year. Due to the highly contagious Delta variant, I'm also wearing an N95 mask when I'm out shopping etc... Study shows why second dose of COVID-19 vaccine shouldn’t be skipped med.stanford.edu A different type of vaccine The Pfizer vaccine, like the one made by Moderna Inc., works quite differently from the classic vaccines composed of live or dead pathogens, individual proteins or carbohydrates that train the immune system to zero in on a particular microbe and wipe it out. The Pfizer and Moderna vaccines instead contain genetic recipes for manufacturing the spike protein that SARS-CoV-2, the virus that causes COVID-19, uses to latch on to cells it infects. In December 2020, Stanford Medicine began inoculating people with the Pfizer vaccine. This spurred Pulendran’s desire to assemble a complete report card on the immune response to it. The team selected 56 healthy volunteers and drew blood samples from them at multiple time points preceding and following the first and second shots. The researchers found that the first shot increases SARS-CoV-2-specific antibody levels, as expected, but not nearly as much as the second shot does. The second shot also does things the first shot doesn’t do, or barely does. “The second shot has powerful beneficial effects that far exceed those of the first shot,” Pulendran said. “It stimulated a manifold increase in antibody levels, a terrific T-cell response that was absent after the first shot alone, and a strikingly enhanced innate immune response.” Unexpectedly, Pulendran said, the vaccine — particularly the second dose — caused the massive mobilization of a newly discovered group of first-responder cells that are normally scarce and quiescent. First identified in a recent vaccine study led by Pulendran, these cells — a small subset of generally abundant cells called monocytes that express high levels of antiviral genes — barely budge in response to an actual COVID-19 infection. But the Pfizer vaccine induced them. This special group of monocytes, which are part of the innate museum, constituted only 0.01% of all circulating blood cells prior to vaccination. But after the second Pfizer-vaccine shot, their numbers expanded 100-fold to account for a full 1% of all blood cells. In addition, their disposition became less inflammatory but more intensely antiviral. They seem uniquely capable of providing broad protection against diverse viral infections, Pulendran said. “The extraordinary increase in the frequency of these cells, just a day following booster immunization, is surprising,” Pulendran said. “It’s possible that these cells may be able to mount a holding action against not only SARS-CoV-2 but against other viruses as well.”